A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03473743 |
Recruitment Status :
Active, not recruiting
First Posted : March 22, 2018
Results First Posted : October 25, 2023
Last Update Posted : April 25, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urothelial Carcinoma | Drug: Erdafitinib Drug: Cetrelimab Drug: Cisplatin Drug: Carboplatin | Phase 1 Phase 2 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 125 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer |
Actual Study Start Date : | April 5, 2018 |
Actual Primary Completion Date : | September 30, 2022 |
Estimated Study Completion Date : | June 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase 1b: Dose Escalation
Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
|
Drug: Erdafitinib
Participants will receive erdafitinib orally.
Other Name: JNJ-42756493 Drug: Cetrelimab Participants will receive cetrelimab by intravenous infusion.
Other Name: JNJ-63723283 Drug: Cisplatin Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy. Drug: Carboplatin Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy. |
Experimental: Phase 2: Dose Expansion
The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
|
Drug: Erdafitinib
Participants will receive erdafitinib orally.
Other Name: JNJ-42756493 Drug: Cetrelimab Participants will receive cetrelimab by intravenous infusion.
Other Name: JNJ-63723283 |
- Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs) [ Time Frame: Up to 8 weeks ]Number of participants with DLTs were reported. The DLTs as per National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE version 5.0) are specific adverse events defined as grade 3 (severe), grade 4 (life-threatening), and grade 5 (death) non-hematological toxicity or hematological toxicity.
- Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment [ Time Frame: From Day 1 up to 36 months ]ORR is defined as the percentage of participants who achieved confirmed complete response (CR) or confirmed partial response (PR), according to response evaluation criteria in solid tumors (RECIST) version1.1. As per RECIST version 1.1, CR: disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR: greater than or equal to (>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions.
- Phase 2: Number of Participants With Treatment-emergent Adverse Event (TEAEs) [ Time Frame: From Day 1 up to 36 months ]Number of participants with TEAEs were reported. An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs were defined as adverse events with onset or worsening on or after date of first dose of study treatment.
- Phase 1b and Phase 2: Plasma Concentration of Erdafitinib [ Time Frame: Up to 6 years 1 month ]
- Phase 1b and Phase 2: Serum Concentration of Cetrelimab [ Time Frame: Up to 6 years 1 month ]
- Phase 1b: Plasma Concentration of Platinum (Cisplatin and Carboplatin) Chemotherapy [ Time Frame: Up to 6 years 1 month ]
- Phase 1b and Phase 2: Number of Participants With Anti-Cetrelimab Antibodies [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Number of Participants With Serious Adverse Events (SAEs) [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Number of Participants With Abnormal Laboratory Values [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Duration of Response (DoR) [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Time to Response (TTR) [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Progression-free Survival (PFS) [ Time Frame: Up to 6 years 1 month ]
- Phase 2: Overall Survival (OS) [ Time Frame: Up to 6 years 1 month ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologic demonstration of transitional cell carcinoma of the urothelium. Variant urothelial carcinoma histologies such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Metastatic or locally advanced urothelial cancer
- Must have measurable disease by radiological imaging according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
- Prior systemic therapy for metastatic urothelial cancer: (a) For Phase 1b erdafitinib + cetrelimab cohort: Any number of lines of prior therapy; (b) For Phase 1b erdafitinib + cetrelimab + platinum chemotherapy cohort: No prior systemic therapy for metastatic disease; and renal function for participants must have a creatinine clearance (CrCl) greater than (>) 30 milliliter per minute (mL/min) to receive carboplatin and >60 mL/min to receive cisplatin as calculated by Cockcroft Gault and (c) Phase 2: No prior systemic therapy for metastatic disease and cisplatin-ineligible based on: ECOG PS 0-1 and at least one of the following criteria: Renal function defined as creatinine clearance (CrCl) less than (˂) 60 mL/min as calculated by Cockcroft-Gault; Grade 2 or higher peripheral neuropathy per NCI-CTCAE version 5.0; Grade 2 or higher hearing loss per NCI-CTCAE version 5.0 OR ECOG PS 2
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of: (a) Phase 1b erdafitinib + cetrelimab cohort: ECOG 0-2; (b) Phase 1b erdafitinib + cetrelimab + platinum chemotherapy cohort: ECOG 0-1 for cisplatin and 0-2 for carboplatin (c) Phase 2: ECOG 0-2
Exclusion Criteria:
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to Cycle 1 Day 1. For Phase 1b, participants who have received the following prior antitumor therapy: received nitrosoureas and mitomycin C within 6 weeks
- Phase 1b erdafitinib + cetrelimab cohort: Chemotherapy within 3 weeks of Cycle 1 Day 1; Phase 1b erdafitinib + cetrelimab + platinum chemotherapy cohort and Phase 2: Prior neoadjuvant/adjuvant chemotherapy is allowed if the last dose was given >12 months prior to recurrent disease progression and did not result in drug-related toxicity leading to treatment discontinuation
- Prior anti-programmed death receptor-1 (PD-1), anti-programmed death ligand-1 (PD-L1), or anti-programmed death ligand-2 (PD-L2) therapy. Prior neoadjuvant/adjuvant checkpoint inhibitor therapy is allowed if the last dose was given more than (>)12 months prior to recurrent disease progression and did not result in drug-related toxicity leading to treatment discontinuation. PD-1 for non-muscle invasive bladder cancer is also allowed
- Active malignancies requiring concurrent therapy other than urothelial cancer
- Symptomatic central nervous system metastases
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03473743
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Documents provided by Janssen Research & Development, LLC:
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT03473743 |
Other Study ID Numbers: |
CR108445 2017-001980-19 ( EudraCT Number ) 42756493BLC2002 ( Other Identifier: Janssen Research & Development, LLC ) 2023-510295-31-00 ( Registry Identifier: EUCT number ) |
First Posted: | March 22, 2018 Key Record Dates |
Results First Posted: | October 25, 2023 |
Last Update Posted: | April 25, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma, Transitional Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Carboplatin Antineoplastic Agents |